Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Björk

Showing results (1-10 of 43) with videos related to

Pageof 5
Sort By:
International Journal of Pharmaceutics|February 17, 2000
Nasal absorption of (S)-UH-301 and its transport into the cerebrospinal fluid of ratsM Dahlin, E Björk
Journal of Drug Targeting|November 22, 2002
Visualization of in vivo olfactory uptake and transfer using fluorescein dextranB Jansson, E Björk
International Journal of Pharmaceutics|February 13, 2001
Nasal administration of a physostigmine analogue (NXX-066) for Alzheimer's disease to ratsM Dahlin, E Björk
Autoimmunity|January 1, 1997
Beta-cell rest: a strategy for the prevention of autoimmune diabetesF A Karlsson, E Björk
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|July 18, 2001
Levels of dopamine in blood and brain following nasal administration to ratsM Dahlin, B Jansson, E Björk
Journal of Pharmacological Methods|July 1, 1984
The effect of changes in sound pressure level and frequency on the seizure response of audiogenic seizure susceptible ratsU Tacke, E Björk, J Tuomisto
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|December 10, 1998
Nasal drug delivery--evaluation of an in vitro model using porcine nasal mucosaC Wadell, E Björk, O Camber
Pharmaceutical Research|March 6, 1998
The influence of intestinal mucus components on the diffusion of drugsA W Larhed, P Artursson, E Björk
Diabetes Care|April 16, 1998
Induction of beta-cell rest in type 1 diabetes. Studies on the effects of octreotide and diazoxideE Björk, C Berne, F A Karlsson
Clinical Pharmacology and Therapeutics|April 5, 2008
Models for plasma glucose, HbA1c, and hemoglobin interrelationships in patients with type 2 diabetes following tesaglitazar treatmentB Hamrén, E Björk, M Sunzel, et al.
Pageof 5

Showing results (1-10 of 43) with videos related to

Sort By:
Pageof 5
International Journal of Pharmaceutics|February 17, 2000
Nasal absorption of (S)-UH-301 and its transport into the cerebrospinal fluid of ratsM Dahlin, E Björk
Journal of Drug Targeting|November 22, 2002
Visualization of in vivo olfactory uptake and transfer using fluorescein dextranB Jansson, E Björk
International Journal of Pharmaceutics|February 13, 2001
Nasal administration of a physostigmine analogue (NXX-066) for Alzheimer's disease to ratsM Dahlin, E Björk
Autoimmunity|January 1, 1997
Beta-cell rest: a strategy for the prevention of autoimmune diabetesF A Karlsson, E Björk
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|July 18, 2001
Levels of dopamine in blood and brain following nasal administration to ratsM Dahlin, B Jansson, E Björk
Journal of Pharmacological Methods|July 1, 1984
The effect of changes in sound pressure level and frequency on the seizure response of audiogenic seizure susceptible ratsU Tacke, E Björk, J Tuomisto
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|December 10, 1998
Nasal drug delivery--evaluation of an in vitro model using porcine nasal mucosaC Wadell, E Björk, O Camber
Pharmaceutical Research|March 6, 1998
The influence of intestinal mucus components on the diffusion of drugsA W Larhed, P Artursson, E Björk
Diabetes Care|April 16, 1998
Induction of beta-cell rest in type 1 diabetes. Studies on the effects of octreotide and diazoxideE Björk, C Berne, F A Karlsson
Clinical Pharmacology and Therapeutics|April 5, 2008
Models for plasma glucose, HbA1c, and hemoglobin interrelationships in patients with type 2 diabetes following tesaglitazar treatmentB Hamrén, E Björk, M Sunzel, et al.
Pageof 5